Prognostic and immunological significance of peroxisome proliferator-activated receptor gamma in hepatocellular carcinoma based on multiple databases

Wang, Chaoban; Shibata, Yu; Qian, Rengcheng; Chen, Shaohe; Dai, Chengjun; Shan, Xiaoou

doi:10.21037/tcr-21-2853

Cited by 4 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, dyslipidemia often accompanies obesity and can result in the accumulation of lipids in hepatocytes, which can progress to MASH, liver cirrhosis, and eventually HCC. Peroxisome proliferator-activated receptor gamma (PPAR-γ) and sterol regulatory element-binding protein-1c (SREBP-1c) are key transcription factors that regulate lipid metabolism and are implicated in the link between obesity and HCC [155]. Activation of these pathways leads to increased lipid synthesis and storage, contributing to liver carcinogenesis.…”

Section: Discussionmentioning

confidence: 99%

Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches

Arvanitakis,

Papadakos,

Lekakis

et al. 2023

IJMS

View full text Add to dashboard Cite

The escalating global prevalence of obesity and its intricate association with the development of hepatocellular carcinoma (HCC) pose a substantial challenge to public health. Obesity, acknowledged as a pervasive epidemic, is linked to an array of chronic diseases, including HCC, catalyzing the need for a comprehensive understanding of its molecular underpinnings. Notably, HCC has emerged as a leading malignancy with rising incidence and mortality. The transition from viral etiologies to the prominence of metabolic dysfunction-associated fatty liver disease (MAFLD)-related HCC underscores the urgent need to explore the intricate molecular pathways linking obesity and hepatic carcinogenesis. This review delves into the interwoven landscape of molecular carcinogenesis in the context of obesity-driven HCC while also navigating using the current therapeutic strategies and future prospects for combating obesity-related HCC. We underscore the pivotal role of obesity as a risk factor and propose an integrated approach encompassing lifestyle interventions, pharmacotherapy, and the exploration of emerging targeted therapies. As the obesity-HCC nexus continues to challenge healthcare systems globally, a comprehensive understanding of the intricate molecular mechanisms and innovative therapeutic strategies is imperative to alleviate the rising burden of this dual menace.

show abstract

Section: Discussionmentioning

confidence: 99%

Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches

Arvanitakis,

Papadakos,

Lekakis

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Another study found that in the HCC cohort, the simultaneous high expressions of USP22/PPARγ/ACACA were associated with poor OS 64 . Through bioinformatics analysis and experimental validation, Wang et al 82 . have discovered that there is a positive correlation between PPARγ and TP53 mutation in HCC, and the high expression of PPARγ indicates a poor prognosis.…”

Section: Ppars and Related Pathways As Prognostic Biomarkersmentioning

confidence: 99%

“… 64 Through bioinformatics analysis and experimental validation, Wang et al. 82 have discovered that there is a positive correlation between PPARγ and TP53 mutation in HCC, and the high expression of PPARγ indicates a poor prognosis. Immunohistochemistry was used to detect the expression of PPARγ in 83 HCC tissues, and the relationship between the PPARγ expression and clinical pathology was analysed.…”

Section: Ppars and Related Pathways As Prognostic Biomarkersmentioning

confidence: 99%

Roles of peroxisome proliferator‐activated receptors in hepatocellular carcinoma

Zhao,

Tan,

Zhang

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), the main pathological type of liver cancer, is linked to risk factors such as viral hepatitis, alcohol intake and non‐alcoholic fatty liver disease (NAFLD). Recent advances have greatly improved our understanding that NAFLD is playing a major risk factor for HCC. Peroxisome proliferator‐activated receptors (PPARs) are a class of transcription factors divided into three subtypes: PPARα (PPARA), PPARδ/β (PPARD) and PPARγ (PPARG). As important nuclear receptors, PPARs are involved in many physiological processes, and PPARs can improve NAFLD by regulating lipid metabolism, accelerating fatty acid oxidation and inhibiting inflammation. In recent years, some studies have shown that PPARs can participate in the occurrence and development of HCC by regulating metabolic pathways. In addition, PPAR modulators have been reported to inhibit the proliferation and metastasis of HCC cells and can enhance the curative effect of conventional treatments. This article reviews the role of PPARs in the occurrence and development of HCC, as well as its value in the diagnosis, treatment and prognosis of HCC, in order to provide directions for future research.

show abstract

Integrated Analysis of POL Family Gene Mutations in AML: Clinical Features, Prognosis, and Bioinformatics Insights

Wu,

wang,

Tang

et al. 2024

Preprint

View full text Add to dashboard Cite

Introduction: The long-term prognosis of acute myeloid leukemia (AML) is challenging due to limited understanding of the molecular markers involved in its development. This study investigates the role of DNA polymerases in AML to offer new insights for diagnosis and treatment. Methods A retrospective study on pediatric AML patients with POL gene family mutations from 2021 to 2024 was conducted. Patients were categorized based on risk stratification criteria, and the DAH regimen was used for induction chemotherapy. Bioinformatics analysis integrated data from various databases to identify key genes and develop survival analysis plots and AUC curves. Results The study included 59 pediatric AML patients, revealing no significant differences in demographic or clinical characteristics between those with and without POL family gene mutations. However, patients with POL gene mutations showed higher complete remission rates after initial DAH chemotherapy (91.67% vs. 59.57%, P = 0.03607), indicating a potential treatment benefit. High expression of four POL genes (POLD1, POLE, POLG, POLQ) in bone marrow and immune cells suggests their crucial role in hematopoiesis and immune response. Survival analysis across different datasets indicated that AML patients with overexpressed POL family genes had significantly worse outcomes, proposing these genes as potential prognostic biomarkers for AML. Discussion This study on pediatric AML demonstrates that POL gene family mutations are associated with higher remission rates post-chemotherapy, indicating their potential as prognostic markers. Bioinformatics analysis emphasizes the significance of these mutations in AML, highlighting their impact on disease prognosis.

show abstract

Prognostic and immunological significance of peroxisome proliferator-activated receptor gamma in hepatocellular carcinoma based on multiple databases

Cited by 4 publications

References 25 publications

Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches

Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches

Roles of peroxisome proliferator‐activated receptors in hepatocellular carcinoma

Integrated Analysis of POL Family Gene Mutations in AML: Clinical Features, Prognosis, and Bioinformatics Insights

Contact Info

Product

Resources

About